Samsung Biologics (207940) Stock Price, Fundamentals & Analysis

What 207940 does

Samsung Biologics (207940) is a contract development and manufacturing organization (CDMO) that produces biopharmaceuticals for partners across South Korea, Europe, and the United States. Its services span late discovery, cell line and process development, analytical development, and non-GMP / CGMP manufacturing, along with aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support. The company also manufactures drug substance and develops antibody-drug conjugates and mRNA products. Founded in 2011 and headquartered in Incheon, South Korea, Samsung Biologics operates in the Healthcare sector, specifically Biotechnology, and is listed on the Korea Exchange. It is part of the KOSPI 200 and has peers such as SK Bioscience (302440), Celltrion (068270), SK Biopharm (326030), Samsung Epis (0126Z0), Daewoong Pharmaceutical (069620), Daewoong (003090), and Hanall Biopharma (009420).

Key numbers explained

• 1,366,000 KRW is the current share price, the amount you would pay for one share right now.
• -1.8% is today's price change, showing the stock moved down by that percentage on the current trading day.
• 63.23T KRW is the market capitalization, the total value of all outstanding shares; it places the company among the largest on the Korea Exchange.
• 27.8 is the forward P/E ratio, which divides the share price by expected future earnings; it tells you how much investors are paying for each unit of expected profit.
• 0% is the share of earnings paid out as dividends, meaning the company currently returns no cash to shareholders through dividends.
• 0.21 is the beta, a measure of volatility relative to the market; a beta below 1 suggests the stock tends to move less than the overall market.
• 1,228,000 – 1,987,000 KRW is the 52-week price range, the lowest and highest traded price over the past year.
• -11.4% is the price change over the last 52 weeks, showing the total return from one year ago to the current price.
• 5.12T KRW is the trailing 12-month revenue, the total sales over the most recent four quarters.
• 30.2% is the year-over-year revenue growth, indicating how much sales have increased compared to the same period a year earlier.
• 38.7% is the profit margin, the percentage of revenue that remains as net profit after all expenses.
• 44.4% is the operating margin, the percentage of revenue left after covering operating costs but before interest and taxes.
• 18.5% is the return on equity, showing how effectively the company generates profit from shareholders' equity.
• 14.8% is the debt-to-equity ratio, a leverage measure comparing total debt to shareholders' equity.

What to watch

• Samsung Biologics operates in the biotechnology CDMO space, where demand is tied to pharmaceutical partners' pipelines and clinical-stage programs.
• As a Korea Exchange stock, it can be influenced by Korean market sentiment, currency movements, and regional regulatory developments.
• The company's revenue growth of 30.2% and strong margins suggest it benefits from scaling manufacturing capacity and expanding its service portfolio.
• A 0% dividend payout means total return depends entirely on price appreciation, which can be sensitive to earnings updates and contract wins.
• The next earnings release is scheduled for Oct 27, 2026, which typically brings updated guidance and operational commentary.